Symptoms of Ovarian Cancer

The rate of new cases of ovarian cancer was 10.9 per 100,000 women per year. The death rate was 6.5 per 100,000 women per year. These rates are age-adjusted and based on 2014–2018 cases and 2015–2019 deaths. BioChain’s tissue arrays or tissue microarrays (TMAs) are a useful tool in biomarker research and drug target validation. It consists of paraffin blocks that are assembled in array fashion to allow multiplex histological analysis. BioChain’s TMAs provide a valuable tool for analysis of protein, RNA, or DNA molecules in oncology, both the malignant and metastatic markers. TMAs can also been constructed with tissues from other diseases and species.

As per an article published on Jama Network "An imaging drug that can help surgeons identify ovarian cancer lesions that may otherwise go undetected has received?FDA approval. Pafolacianine, marketed as Cytalux, is a targeted fluorescent imaging agent that illuminates ovarian cancer during surgery. Administered intravenously as little as an hour before surgery, pafolacianine binds to folate receptors, which often are overexpressed in ovarian cancer. Under fluorescent light, the drug illuminates cancerous tissue. The FDA has cleared a near-infrared fluorescence imaging system specifically for use with pafolacianine"